More than two dozen New Haven city officials and local public-education leaders gathered in the library of Career High School at 140 Legion Ave. to celebrate a new fund, which will be seeded with $200,000 from developer Carter Winstanley as part of a community benefits agreement related to the 101 College St. project nearby.
City Economic Development Administrator Michael Piscitelli said on Tuesday that the fund will provide up to $3,000 per year for up to two years for students from the Hill, Dwight, and downtown neighborhoods who enroll in bioscience and STEM-related programs at Gateway Community College.
The fund will also provide up to $5,000 per year for up to four years for students from those same three neighborhoods if they enroll in the Biopath program at Southern Connecticut State University (SCSU).
Enko has raised additional funding, bringing the company’s overall capital raised to date to $150 million. Enko will use the new funds to advance the company’s product pipeline of novel crop protection chemistries and provide critical solutions for large scale global food security challenges.
“Ag-bio companies like Enko are at the leading edge of applying new digital tools to drive innovation and future proof our food supply,” said Dr. Prem Pavoor, Senior Partner, Head of India & Healthcare Investments, Eight Roads Ventures. “By investing in better crop protection, we can help improve yields, reduce waste, and create more sustainable food systems for our growing population in an increasingly unstable world.”
|
|||||||||||||||||||||||
|
|||||||||||||||||||||||
|
ConnCAT – one of the states leading job training and skill-building organizations – is teaming up with Yale to launch a program to train New Haven residents without college degrees to meet the needs of industry leaders.
BioLaunch, as the program is called, is a state-funded partnership of local biotech companies to create internship opportunities targeting Newhallville/Dixwell residents.
Connecticut Innovations, the state’s strategic venture capital arm, has launched a new fund committed to investing in early-stage companies, with an emphasis on underrepresented founders.
The Future Fund is looking to invest in venture-backable, tech-enabled startups showing high growth potential. Investment sizes will range from $250,000 to $1.5 million. Although the fund will prioritize disruptive startups in the largest and growing markets, any innovative, early-stage company with diversity at the board or executive level may apply for consideration.
|
||||||||||||||||||
|
||||||||||||||||||
|
BioMed X has had an ongoing research collaboration with the Illinois-based pharmaceutical business AbbVie. Their first joint research project, in Germany, focused on Alzheimer’s disease.
|
|||||||||||||
|
|||||||||||||
|
Boehringer Ingelheim and Eli Lilly and Company announced that the FDA has accepted a supplemental New Drug Application for Jardiance® (empagliflozin) tablets. The tablets are being investigated as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD).
“There is a significant need for additional therapies that reduce the risk of kidney disease progression and hospitalizations in adults with CKD,” said Mohamed Eid, M.D., M.P.H., M.H.A., vice president, Clinical Development & Medical Affairs, Cardio-Renal-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals.”
In an effort to practice precision medicine — a medical movement to develop specific treatments for individual patients — scientists created software to quantify and differentiate the impacts of variants occurring in cancer.
The software was developed by Jeffrey Townsend, professor of biostatistics and ecology and evolutionary biology at Yale School of Public Health, Jeffrey Mandell, first author and a doctoral student in Townsend’s lab and Vincent Cannatro, assistant professor of biology at Emmanuel College.
In an effort to practice precision medicine — a medical movement to develop specific treatments for individual patients — scientists created software to quantify and differentiate the impacts of variants occurring in cancer.
The software was developed by Jeffrey Townsend, professor of biostatistics and ecology and evolutionary biology at Yale School of Public Health, Jeffrey Mandell, first author and a doctoral student in Townsend’s lab and Vincent Cannatro, assistant professor of biology at Emmanuel College.